Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Chronic Kidney Disease in Assiut
NCT ID: NCT06009250
Last Updated: 2023-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2023-12-31
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main question\[s\] it aims to answer are:
* \[question 1\] prevalence of NAFLD in CKD patients.
* \[question 2\] the relationship between NAFLD and CKD.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Association Betweenq MAFLD ( Metabolic Associated Fatty Liver Disease) and Chronic Kidney Disease
NCT06135467
NAFLD Among Patients With Type 2 Diabetes and CKD
NCT03826381
Serum Adiponectin as an Early Marker for Renal Impairment in Patients With Non-alcoholic Fatty Liver Disease.
NCT05106049
De Novo Lipogenesis in Severity of NAFLD
NCT03683589
Role Of Serum Adiponectin In The Ealy Detection Of Renal Impairment In Patients With Non Alcoholic Fatty Liver Disease
NCT05556135
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main question\[s\] it aims to answer are:
* \[question 1\] prevalence of NAFLD in CKD patients.
* \[question 2\] the relationship between NAFLD and CKD.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CKD patients
CKD patient who are not DM are investigated for the presence of NAFLD
No interventions assigned to this group
normal control group
normal population are investigated to know the prevalence of NAFLD in contrast to patients with CKD.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Alcoholics
* patient on Hemodialysis
* patients with wilson disease
* patients with alpha one antitrypsin deficiency
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Muhammad Ameen Abdelrady Abdelaziz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Muhammad Ameen Abdelrady Abdelaziz
Internal Medicine Resident
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NAFLD and CKD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.